Skip to main navigation
  • OUR COMPANY
    • Our Purpose
    • Our Leadership
    • Our Locations
  • OUR FOCUS
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • OUR SCIENCE
    • Pipeline
    • Relugolix Combination Tablet
    • MVT-602
  • OUR MEDICINES
  • OUR ADVOCACY
    • Forward Together
  • JOIN THE TEAM
    • Our Culture
    • Our Benefits
    • Open Positions
  • Investors & Media
    • Company Overview
    • News & Events
      • Press Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Board of Directors
      • Documents & Charters
      • Committee Composition
      • Expanded Access
    • Email Alerts
  • Contact Us
  • Twitter
  • LinkedIn

Press Releases

Press Releases

March 10, 2023
Sumitovant Biopharma Completes Acquisition of Myovant Sciences
January 26, 2023
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Toolkit

Print Page
RSS Feeds
Email Alerts
Contact
Search
  • OUR COMPANY
    • Our Purpose
    • Our Leadership
    • Our Locations
  • OUR FOCUS
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • OUR SCIENCE
    • Pipeline
    • Relugolix Combination Tablet
    • MVT-602
  • OUR MEDICINES
  • OUR ADVOCACY
    • Forward Together
  • JOIN THE TEAM
    • Our Culture
    • Our Benefits
    • Open Positions
  • Investors & Media
    • Company Overview
    • News & Events
    • Stock Information
    • Financials & Filings
    • Corporate Governance
    • Email Alerts
  • Contact Us
© 2024 Myovant Sciences GmbH. All rights reserved.
Terms of Use Privacy Policy Cookie Policy Compliance & Prescriber Information